Table 1.
Incidence of individual mutations across the four non small-cell lung cancer patient subgroups
| Gene | Incidence of mutation, n/N (%) |
|||
|---|---|---|---|---|
| Western/ADC | Western/SCC | Asian/ADC | Asian/SCC | |
| TP53a | 164/532 (30.8) | 62/113 (54.9) | 325/978 (33.2) | 64/179 (35.8) |
| EGFRa | 940/4890 (19.2) | 11/334 (3.3) | 1492/3117 (47.9) | 22/474 (4.6) |
| KRASa | 613/2352 (26.1) | 12/187 (6.4) | 236/2114 (11.2) | 5/284 (1.8) |
| LKB1a | 99/610 (16.2) | 13/137 (9.5) | 22/550 (4.0) | 0/166 (0.0) |
| EML4-ALK | 55/856 (6.4) | 4/89 (4.5) | 71/1326 (5.4) | 5/277 (1.8) |
| PTENa | 25/419 (6.0) | 0/12 (0.0) | 4/248 (1.6) | 12/123 (9.8) |
| BRAFa | 66/2028 (3.3) | 1/408 (0.2) | 5/321 (1.6) | 0/124 (0.0) |
| PIK3CA | 6/475 (1.3) | 1/71 (1.4) | 4/235 (1.7) | 8/124 (6.5) |
| ErbB2 | 7/505 (1.4) | 2/117 (1.7) | 20/712 (2.8) | 1/259 (0.4) |
aSignificant differences between patient subgroups were observed in the incidences of mutations in the following genes:
TP53: Western/ADC versus Western/SCC (Pcorr = 3.2 × 10−4).
EGFR: Western/ADC versus Western/SCC (Pcorr = 2.6 × 10−15); Western/ADC versus Asian/ADC (Pcorr = 1.7 × 10−158); Asian/ADC versus Asian/SCC (Pcorr = 1.8 × 10−85).
KRAS: Western/ADC versus Western/SCC (Pcorr = 3.4 × 10−9); Western/ADC versus Asian/ADC (Pcorr = 1.1 × 10−35); Asian/ADC versus Asian/SCC (Pcorr = 1.6 × 10−6).
LKB1: Western/ADC versus Asian/ADC (Pcorr = 3.2 × 10−10); Western/SCC versus Asian/SCC (Pcorr = 3.3 × 10−3).
PTEN: Asian/ADC versus Asian/SCC (Pcorr = 8.3 × 10−3).
BRAF: Western/ADC versus Western/SCC (Pcorr = 1.3 × 10−2).
ADC, adenocarcinoma; SCC, squamous cell carcinoma.